Literature DB >> 1809448

Continuous epidural methadone treatment for cancer pain.

Y Shir1, S S Shapira, Z Shenkman, B Kaufman, F Magora.   

Abstract

Seventy cancer patients suffering from visceral or somatic pain received continuous epidural methadone (EM) analgesia. Initially, 4 mg of 0.1% methadone was given three times daily. If this dose proved ineffective, it was gradually increased to 8 mg four times daily. With this regimen good pain control was obtained in 56 patients (80%). Patients continued the EM therapy for periods up to 140 days, with an average duration of 27 days. Morphine was substituted for methadone in 14 patients (20%). Four of these patients responded well and continued treatment for an average of 18 days. No serious side effects have been observed with EM. With a proper selection of patients and following strict therapy guidelines, epidural methadone is efficacious in treating cancer pain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1809448     DOI: 10.1097/00002508-199112000-00014

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  4 in total

Review 1.  Implantable intrathecal pumps for chronic pain: highlights and updates.

Authors:  Karen H Knight; Frances M Brand; Ali S Mchaourab; Giorgio Veneziano
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

Review 2.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

3.  Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neuroaxial agents: the first experience.

Authors:  Y Eugene Mironer; C David Tollison
Journal:  Neuromodulation       Date:  2001-01

4.  Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone.

Authors:  G R Lauretti; C C Rizzo; A L Mattos; S W Rodrigues
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.